# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(5.13) per share.
https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_07082024_REVB_Sorensen.pdf
Revelation Biosciences reveals positive safety and biomarker data from its Phase 1 study (RVL-HV02) of Gemini. The study met it...
-Gemini administration induced statistically significant, dose dependent changes in key biomarkers of activity--Gemini was safe...
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(2.46) per share which missed the analyst consensus estimate...